GU Cancers 2025 | Phase I trial of cabozantinib and nivolumab ± CBM588 in metastatic RCC
Hedyeh Ebrahimi
• 14 Feb 2025
Hedyeh Ebrahimi, MD, MPH, City of Hope Comprehensive Cancer Center, Duarte, CA, discusses updated outcomes from a Phase I trial (NCT05122546) of cabozantinib and nivolumab with or without CBM588, a live bacterial product, in metastatic renal cell carcinoma (mRCC). The addition of CBM588 was associated with higher response rates and prolonged progression-free survival compared to cabozantinib and nivolumab alone. The combination maintained a manageable safety profile, with no new safety signals observed. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
